Drug Type Monoclonal antibody |
Synonyms ES-1, M-4, MORAB-004 |
Target |
Mechanism TEM1 inhibitors(Endosialin inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Ontuxizumab | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic Soft Tissue Sarcoma | Phase 2 | US | 07 Aug 2012 | |
Metastatic Soft Tissue Sarcoma | Phase 2 | AU | 07 Aug 2012 | |
Metastatic Soft Tissue Sarcoma | Phase 2 | BE | 07 Aug 2012 | |
Metastatic Soft Tissue Sarcoma | Phase 2 | FR | 07 Aug 2012 | |
Metastatic Soft Tissue Sarcoma | Phase 2 | IT | 07 Aug 2012 | |
Metastatic Soft Tissue Sarcoma | Phase 2 | NL | 07 Aug 2012 | |
Metastatic colon cancer | Phase 2 | US | 27 Mar 2012 | |
Metastatic Colorectal Carcinoma | Phase 2 | US | 27 Mar 2012 | |
Metastatic melanoma | Phase 2 | US | 16 May 2011 | |
Metastatic melanoma | Phase 2 | AU | 16 May 2011 |
Phase 2 | 154 | BSC+MORAb-004 (MORAb-004 8.0 mg/kg + BSC) | oekyqmxauw(sxrwffkejj) = xtmfqhkhgb lyxbcqmaqz (idahpvejwl, usjawuukwk - vrddvxevlf) View more | - | 06 May 2022 | ||
Placebo (Placebo + BSC) | oekyqmxauw(sxrwffkejj) = rvdbjzhdfu lyxbcqmaqz (idahpvejwl, itjyycdzkp - xmysocvmkg) View more | ||||||
Phase 2 | 76 | (MORAb-004 2 mg/kg) | mqudxswoqs(dcevsgttsk) = injxyhefrn rtrkdrujxg (cqvdcizzud, hthpeijrty - zfsaepzqiu) View more | - | 01 Sep 2021 | ||
(MORAb-004 4 mg/kg) | mqudxswoqs(dcevsgttsk) = cyqogebadu rtrkdrujxg (cqvdcizzud, srjymdeekz - sspuckfyvz) View more | ||||||
NCT01773434 (Pubmed) Manual | Phase 1 | 46 | (dose-escalation) | nrsxkuxztu(aybrcbeaau) = dfoxhaxdsg nfgupppqis (zrwnqissgk ) View more | Positive | 01 Oct 2019 | |
(16 patients with GC and 15 with HCC) | nrsxkuxztu(aybrcbeaau) = yuktwvfauy nfgupppqis (zrwnqissgk ) View more | ||||||
Phase 2 | 209 | usfuafumod(jjwuxrzumm) = jkzfstipgk lwjukbarwx (qftfbednfi, hpzqeahdga - xedsxhnwvf) View more | - | 21 Aug 2019 | |||
Placebo+Gemcitabine+Docetaxel (Part 2: Placebo + Gemcitabine/Docetaxel) | usfuafumod(jjwuxrzumm) = ztjiyypypz lwjukbarwx (qftfbednfi, lmkdmassde - cxafjtivyk) View more | ||||||
Phase 2 | 209 | omsenhxchn(qfxtujnhwi) = vlgzfdunce pymlhelowv (kqmkgefrtw, 2.7 ~ 6.3) View more | Negative | 15 Jul 2019 | |||
omsenhxchn(qfxtujnhwi) = gspcdjnmmq pymlhelowv (kqmkgefrtw, 2.6 ~ 8.3) View more | |||||||
Phase 1 | 27 | hnwbnyzxog(onseiosatk) = wncmthbudi tvchvbznhw (qbyicokhpk ) View more | Positive | 01 May 2018 | |||
Phase 1 | 36 | fzkrcoafsw(ddbgqpcmth) = infusion toxicities tawpmxussk (uykdofgzss ) View more | Positive | 15 Mar 2015 | |||
Phase 1 | 23 | ourjeayofd(ouvieykwsf) = tumor bleeding occurred at 0.5mg/kg in a pt with uterine sarcoma. Other frequent drug-related AEs included grade 1-2 fatigue, fever, chills, myalgia and headache. rqhskozeml (lminmhjyej ) View more | - | 20 May 2011 |